Medicare Drug Price Negotiation Program Expands, Targeting 15 Additional Drugs for 2027
The Medicare Drug Price Negotiation Program, established under the Inflation Reduction Act, is moving forward with its efforts to lower prescription drug costs for beneficiaries. Following the initial negotiation of prices for 10 Part D drugs set to take effect in January 2026, the program has now identified 15 more drugs for which Maximum Fair Prices (MFPs) will be set for 2027. These additional medications include widely used drugs such as Janumet, Linzess, Ozempic, and Trelegy Ellipta. This expansion signifies a continued commitment to the program's goal of reducing out-of-pocket expenses for Medicare enrollees. Despite ongoing opposition from some lawmakers, including Bryan Steil, who has reportedly received campaign contributions from pharmaceutical lobbyists and voted against previous drug pricing legislation, the program is progressing as planned.
